If you take any biologic drug off the shelf today, chances are high it was made inside a Chinese hamster ovary cell. Insulin analogues, cancer-fighting antibodies, clotting factors, and a growing list of gene therapies all trace their manufacturing back to this one remarkably productive cell line.
CHO cells have been the backbone of the biopharmaceutical industry for decades, and their dominance shows no sign of fading. This article explains what CHO cells are, where they came from, why they became the industry standard, and what role they continue to play in modern drug development and production.
What Are CHO Cells?
CHO stands for Chinese Hamster Ovary. These are immortalized cells derived from the ovarian epithelial tissue of the Chinese hamster, a small rodent scientifically known as Cricetulus griseus. In their natural form, these cells would have a finite lifespan. Through decades of laboratory adaptation and genetic modification, however, CHO cells have been developed into a family of robust, continuously dividing cell lines capable of growing in large-scale bioreactor systems.
What makes CHO cells special is not just that they survive in a lab. It is that they can produce complex, biologically active human proteins, complete with the right folding, assembly, and chemical modifications needed to make those proteins safe and effective as medicines.
The History of CHO Cells
The story of CHO cells begins in 1957, when Dr. Theodore T. Puck, a geneticist at what is now the University of Colorado, obtained a single female Chinese hamster from Dr. George Yerganian's laboratory at the Boston Cancer Research Foundation. Puck extracted cells from the hamster's ovary and successfully cultured them in a petri dish, establishing the first CHO cell line.
The choice of the Chinese hamster was intentional. These animals have an unusually low chromosome number, just 11 pairs, which made them easier to work with in cytogenetic and tissue culture experiments compared to other rodents.
For the first two decades after their creation, CHO cells were used primarily for basic genetics research. That changed dramatically in the 1980s with the rise of recombinant DNA technology. Scientists discovered that CHO cells could be engineered to express human proteins, and that those proteins came out with glycosylation patterns remarkably similar to those found in the human body. This single finding transformed CHO cells from a genetics tool into the foundation of the modern biopharmaceutical industry.
In 1987, the first recombinant protein produced in CHO cells, tissue plasminogen activator (tPA), was approved by the FDA for treating blood clots. It was a watershed moment, and it opened the floodgates for what would become a decades-long stream of CHO-derived therapeutics.
Why Are CHO Cells the Industry Standard?
Many mammalian cell lines exist, so why did CHO cells become the dominant choice? The answer comes down to a combination of biological, regulatory, and practical advantages that no other system has fully replicated.
Human-Compatible Glycosylation
Glycosylation refers to the attachment of sugar chains to proteins. These chains affect how a protein folds, how long it stays active in the bloodstream, and how the immune system responds to it. CHO cells perform glycosylation in a way that closely resembles human cells, far more so than bacteria or yeast. This is not a small detail. A protein with the wrong glycan pattern can be inactive, toxic, or cleared too quickly from the body to be therapeutically useful.
Growth in Suspension and Serum-Free Media
CHO cells can be adapted to grow in suspension culture in chemically defined, serum-free media. This is essential for large-scale pharmaceutical manufacturing, where cells must be grown in bioreactors holding thousands of liters of liquid. Serum-free conditions also reduce the risk of contamination from animal-derived components, which is an important regulatory consideration.
High Protein Yields
Through decades of optimization, CHO cells have become remarkably efficient protein factories. Modern fed-batch and perfusion bioreactor processes can achieve recombinant protein yields of several grams per liter, which was unthinkable in the early days of biotechnology.
Established Regulatory Track Record
CHO cells have been used to manufacture approved drugs since 1987. Regulatory agencies including the FDA and the European Medicines Agency have decades of safety data on CHO-derived products. This familiarity makes the approval process more predictable when a new drug is produced using CHO cells compared to a novel or less-established expression system.
Genetic Stability
Well-maintained CHO cell lines are genetically stable over many generations, which is critical in pharmaceutical manufacturing. A production cell line must behave consistently from one manufacturing batch to the next. CHO cells, particularly when properly banked and managed at low passage numbers, deliver this consistency reliably.
Common CHO Cell Line Variants
The original CHO cell line has given rise to several derivative lines, each optimized for specific applications. Understanding the differences helps researchers choose the right variant for their work.
CHO-K1
CHO-K1 is the most widely used subline of the original CHO cell line. It was derived from the parental CHO line by Theodore Puck in the 1950s and remains a standard reference strain in both academic research and commercial manufacturing. CHO-K1 cells can grow adherently or be adapted to suspension culture, and they are the starting point for many engineered variants.
CHO-DG44
CHO-DG44 cells are deficient in the enzyme dihydrofolate reductase (DHFR). This deficiency is deliberately exploited for gene amplification: when researchers introduce a target gene alongside a DHFR gene, and then grow the cells in methotrexate, which blocks DHFR, only cells that have amplified both genes survive. This method can dramatically increase the copy number of the gene of interest and therefore boost protein production. CHO-DG44 has been widely used for manufacturing monoclonal antibodies.
CHO-S
CHO-S is a suspension-adapted variant optimized for serum-free culture. It grows in single-cell suspension without the need for surface attachment, making it ideal for large-scale bioreactor-based production. Gibco's FreeStyle CHO-S is a commercially available version widely used in transient and stable transfection workflows.
GS-CHO
GS-CHO cells use the glutamine synthetase (GS) selection system. Cells are grown in glutamine-free media, and only those that have successfully integrated and expressed the GS gene alongside the gene of interest will survive. This system, developed by Lonza, offers an alternative to DHFR-based amplification and has been used to manufacture several approved biologics.
What Are CHO Cells Used For?
Monoclonal Antibody Production
This is the single largest application of CHO cells in the pharmaceutical industry. Monoclonal antibodies are used to treat cancer, autoimmune diseases, and inflammatory conditions. Drugs like trastuzumab (Herceptin), tocilizumab (Actemra), and adalimumab (Humira) are all produced in CHO cells. The global monoclonal antibody market is worth hundreds of billions of dollars, and the majority of it flows through CHO-based manufacturing.
Recombinant Protein Therapeutics
Beyond antibodies, CHO cells are used to produce a wide range of therapeutic proteins including clotting factors for hemophilia, erythropoietin for anemia, follicle-stimulating hormone for fertility treatment, and enzymes for rare metabolic diseases. These are proteins that the human body either cannot produce in sufficient quantities or produces in a dysfunctional form.
Vaccine Production
CHO cells are increasingly used in vaccine manufacturing, particularly for virus-like particle vaccines and subunit vaccines. Their ability to produce correctly folded, glycosylated proteins makes them suitable for antigens that require proper three-dimensional structure to trigger an immune response. This overlaps significantly with the broader field of infectious disease research, where CHO-derived proteins are being explored as vaccine candidates for multiple pathogens.
Drug Discovery and Screening
In research settings, CHO cells are used to express specific receptors, ion channels, or other drug targets so that scientists can screen compounds against them. This is a common application in early-stage drug discovery and screening workflows, where the goal is to identify which compounds interact with a target of interest before committing to more expensive animal or clinical studies.
Gene Therapy Vector Production
While HEK293 cells are more commonly associated with viral vector production, CHO cells are also used in certain AAV and lentiviral manufacturing processes, particularly in industrial settings where large-scale suspension culture is required.
How CHO Cells Are Cultured
CHO cells are typically grown in chemically defined, serum-free media. The standard formulation for adherent CHO cultures includes Ham's F12 nutrient mixture or DMEM/F12 blend, supplemented with appropriate growth factors. For suspension culture, proprietary commercial media formulations from suppliers like Sigma-Aldrich, Gibco, and others are commonly used.
The doubling time of CHO cells is typically between 18 and 24 hours under optimal conditions, making them relatively fast-growing by mammalian cell standards. In bioreactor production, fed-batch culture is the most common approach, where cells are grown for 10 to 14 days and progressively fed with concentrated nutrient solutions to maintain productivity.
Cryopreservation is used to maintain working and master cell banks, ensuring that manufacturers always have access to certified, low-passage cells with a documented production history.
CHO Cells vs. Other Expression Systems
CHO cells are not the only option for producing biopharmaceuticals. Understanding how they compare to alternatives helps explain why they remain the preferred choice.
Bacterial systems like E. coli are fast and inexpensive but cannot perform mammalian glycosylation. This limits them to simpler proteins like insulin or certain cytokines that do not require glycan modifications for activity.
Yeast systems offer some glycosylation capability but produce glycan patterns that differ meaningfully from human cells, which can affect drug efficacy and immunogenicity.
Other mammalian cell lines such as HEK293, NS0, and BHK-21 are also used in biopharmaceutical production, each with specific advantages for particular applications. HEK293 cells, for example, are often preferred for gene therapy vector manufacturing. You can read more about the HEK293 cell line and why researchers use it in our dedicated guide.
Among all these options, CHO cells occupy a unique position: they combine human-compatible glycosylation, scalability, regulatory acceptance, and a decades-long track record that no other single system can match.
Limitations and Challenges of CHO Cells
Despite their dominance, CHO cells are not without drawbacks.
Cell line development is time-consuming. Generating a stable, high-producing CHO clone for a new biologic can take 12 to 18 months, which creates pressure on drug development timelines. Advances in high-throughput screening and automated cell line development are helping to compress this timeline, but it remains a bottleneck.
CHO cells can also produce proteins with slightly non-human glycan structures. While generally well-tolerated, these differences are sometimes clinically significant and require careful monitoring during development.
Additionally, CHO cells can be sensitive to process changes. Shifts in temperature, pH, dissolved oxygen, or nutrient composition can affect both cell growth and protein quality, requiring careful bioprocess optimization and monitoring.
The Future of CHO Cell Technology
CHO cells are not standing still. The field of CHO cell engineering is highly active, with researchers working to improve yield, reduce development timelines, and fine-tune protein quality.
Genome editing tools including CRISPR-Cas9 are being used to knock out genes that produce unwanted glycan structures, insert landing pads for targeted gene integration, and engineer cells that are more resistant to apoptosis or metabolic stress.
Continuous bioprocessing, where cells are grown in perfusion mode for weeks or months rather than batch mode, is gaining traction as a way to increase productivity while reducing facility footprint. These engineering advances sit at the intersection of cell biology and manufacturing science, reflecting the broader evolution of engineered and stable expression cell lines as a field.
As biologics become an increasingly central part of medicine, CHO cells will remain central to how they are made. The infrastructure, regulatory history, and biological advantages built up over 60 years of development are not easily replicated by newer systems.
Frequently Asked Questions
What does CHO stand for?
CHO stands for Chinese Hamster Ovary. The cells are derived from the ovarian epithelial tissue of the Chinese hamster, Cricetulus griseus.
Why are CHO cells used in biopharmaceutical production?
They can grow at large scale in suspension culture, produce proteins with human-compatible glycosylation, achieve high yields, and have a long regulatory track record with the FDA and other agencies. No other single expression system matches this combination of advantages.
Are CHO cells human cells?
No. CHO cells are derived from Chinese hamster tissue. However, the proteins they produce carry glycan modifications that closely resemble those in human cells, which is why they are preferred for making drugs intended for human use.
What is the doubling time of CHO cells?
Under standard culture conditions, CHO cells typically double every 18 to 24 hours, making them relatively fast-growing among mammalian cell lines.
What is the difference between CHO-K1 and CHO-DG44?
CHO-K1 is a subline of the original CHO cell line used broadly in research and manufacturing. CHO-DG44 is DHFR-deficient, which allows researchers to use methotrexate selection to amplify gene copy numbers and increase recombinant protein expression levels.
Can CHO cells be grown in serum-free media?
Yes. CHO cells can be adapted to grow in chemically defined, serum-free suspension media. This is standard practice in pharmaceutical manufacturing and eliminates the batch-to-batch variability associated with animal-derived serum.
What drugs are made using CHO cells?
Many widely used biologics are produced in CHO cells, including trastuzumab (Herceptin) for breast cancer, tocilizumab (Actemra) for rheumatoid arthritis, etanercept (Enbrel) for autoimmune diseases, and erythropoietin for anemia, among many others.